<DOC>
	<DOCNO>NCT00933608</DOCNO>
	<brief_summary>Recent data show mark cell damage precede clinical manifestation Alzheimer 's disease ( AD ) . Hence , target population risk pharmacological intervention possible strategy lessen burden disease . Cognitively normal individual subjective memory complaint ( SMC ) manifest biological characteristic consistent early AD risk future cognitive decline . Family history AD also constitute risk . In previous study investigator show memantine slows accumulation phosphorylated tau normal SMC subject . Using multivoxel high field MR spectroscopy ( MRS ) technique , investigator also demonstrate memantine decrease hippocampal glutamate . Both finding may consistent drug 's anti-excitotoxic activity . In new project investigator propose treat sample 12 presymptomatic individual risk ( SMC family history AD ) memantine . This double blind , placebo control study control group ( 12 non-treated subject ) . The investigator determine whether effect memantine assess cognitive performance MRS present 4 month treatment persist 2 month discontinuation . MRS use evaluate effect memantine level neurotransmitter glutamate neuronal viability marker N-acetylaspartate ( NAA ) hippocampus . The investigator test follow hypothesis : 1 . In subject SMC , memantine modifying effect brain biochemistry reflect MRS reduction glutamate ( reduced excitotoxicity ) increase NAA ( neuronal integrity ) . 2 . The effect drug persist ( marker sustain neuroprotection ) measure 2 month discontinuation treatment .</brief_summary>
	<brief_title>Effects Memantine Magnetic Resonance ( MR ) Spectroscopy Subjects Risk Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Memantine</mesh_term>
	<criteria>presence subjective memory complaint without objective evidence impair cognition family history Alzheimer 's disease major depression Parkinson 's disease stroke seizure uncontrolled diabetes hypertension current benzodiazepine use substance abuse contraindication MRI contraindication memantine</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>subjective memory complaint</keyword>
	<keyword>cognitively healthy</keyword>
	<keyword>family history</keyword>
	<keyword>AD</keyword>
</DOC>